Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates

Journal of Digestive Diseases

Volumn 15, Issue 9, 2014, Pages 508-513

  Rakici, Halil ^a   Akdoǧan, Remzi Adnan ^a   Bedir, Recep ^a   Copur, Aysegul ^a   Yilmaz, Arif ^a  

^a RECEP TAYYIP ERDOGAN UNIVERSITY   (Turkey)

Author keywords

Eradication rate; Helicobacter pylori; Moxifloxacin; Patients' compliance; Resistance

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; MOXIFLOXACIN; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE;

ADULT; AGED; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMAN; ISOLATION AND PURIFICATION; MALE; MEDICATION COMPLIANCE; MICROBIOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LANSOPRAZOLE; MALE; MEDICATION ADHERENCE; METRONIDAZOLE; MIDDLE AGED; PROTON PUMP INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84906820516     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12171     Document Type: Article

References (33)

1. Peura DA, Crowe SE. Helicobacter pylori. In: Feldman M, Lawrence SF, Lawrence JB, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Pathophysiology, Diagnosis, Management, 9th edn. Toronto: Saunders Elsevier, 2010; 833-843.
2. Malfertheiner P, Megraud F, O'Morain CA etal. Management of Helicobacter pylori infection - the Maastricht IV/Florence consensus report. Gut 2012; 61: 646-664.
3. Dzieniszewski J, Jarosz M. Guidelines in the medical treatment of Helicobacter pylori infection. J Physiol Pharmacol 2006; 57 (Suppl 3): 143-154.
4. Fock KM, Katelaris P, Sugano K etal. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24: 1587-1600.
5. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010; 362: 1597-1604.
6. Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-1825.
7. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001; 121: 1120-1126.
8. Delahay RM, Rugge M. Pathogenesis of Helicobacter pylori infection. Helicobacter 2012; 17 (Suppl 1): 9-15.
9. Amieva MR, El-Omar EM. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology 2008; 134: 306-323.
10. 13C-yrea breath test. BMC Public Health 2013; 13: 1215.
11. Zullo A, Vaira D, Vakil N etal. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003; 17: 719-726.
12. Vaira D, Zullo A, Vakil N etal. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007; 146: 556-563.
13. Tepes B, O'Connor A, Gisbert JP, O'Morain C. Treatment of Helicobacter pylori infection 2012. Helicobacter 2012; 17 (Suppl 1): 36-42.
14. Mégraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17: 1333-1343.
15. Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol 2011; 17: 3971-3975.
16. Qasim A, Sebastian S, Thornton O etal. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005; 21: 91-96.
17. Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: the QUADRATE Study. Gastroenterology 2002; 123: 1763-1769.
18. Dore MP, Marras L, Maragkoudakis E etal. Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen. Helicobacter 2003; 8: 307-309.
19. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008; 148: 923-931.
20. Mégraud F, Marshall BJ. How to treat Helicobacter pylori. First-line, second-line, and future therapies. Gastroenterol Clin North Am 2000; 29: 759-773.
21. Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004; 20: 1071-1082.
22. Graham DY, Osato MS, Hoffman J, Opekun AR, Anderson SY, El-Zimaity HM. Furazolidone combination therapies for Helicobacter pylori infection in the United States. Aliment Pharmacol Ther 2000; 14: 211-215.
23. Wong WM, Gu Q, Lam SK etal. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17: 553-560.
24. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006; 101: 488-496.
25. Ilktac M, Sahin A, Nazik H, Ongen B. Immunochromatographic tests detecting Helicobacter pylori antigen in stool: comparison of the results of eight different commercial kits. ANKEM Derg 2012; 26: 148-153.
26. Yoon H, Kim N, Lee BH etal. Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate. Helicobacter 2009; 14: 77-85.
27. Bago P, Vcev A, Tomic M, Rozankovic M, Marusić M, Bago J. High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. Wien Klin Wochenschr 2007; 119: 372-378.
28. Ciccaglione AF, Cellini L, Grossi L, Marzio L. Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori. World J Gastroenterol 2012; 18: 4386-4390.
29. Di Caro S, Ojetti V, Zocco MA etal. Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002; 16: 527-532.
30. Wang CD, Zhuang ZH, Lu D, Li WQ, Wu T, Chen YL. Efficacy of moxifloxacin-based triple therapy to eradicate Helicobacter pylori infection. Zhonghua Yi Xue Za Zhi 2010; 90: 87-91 (in Chinese).
31. Miehlke S, Krasz S, Schneider-Brachert W etal. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter 2011; 16: 420-426.
32. Bayan K, Yilmaz S, Dursun M, Ozekinci T. The prevalence of primary and secondary Helicobacter pylori resistance to clarithromycin and probable contributing cofactors: data from southeastern Anatolia. Hepatogastroenterology 2008; 55: 289-293.
33. Baglan PH, Bozdayi G, Ozkan M, Ahmed K, Bozdayi MA, Ozden A. Clarithromycin resistance prevalence and iceA gene status in Helicobacter pylori clinical isolates in Turkish patients with duodenal ulcer and functional dyspepsia. J Microbiol 2006; 44: 409-416.